14th ANCA and Vasculitis Workshop 2009

Lund, Sweden and Copenhagen Denmark

15th Vasculitis and ANCA Workshop 2011

Review of presentations in Clinical & Experimental Immunology, Vol 164, Issue Supplement s1, May 2011 –


2012 Revised International Chapel Hill Consensus Conference – Nomenclature of Vasculitis

Conference convened to improve the CHCC 1994 nomenclature, change names and definitions as appropriate, and add important categories of vasculitis that were not included in CHCC 1994. Arthritis & Rheumatism, Vol 65, Issue 1, Jan 2013.


ACR: Azathioprine Bests CellCept for Vasculitis (2010)

Abstract from “Medpage Today” – (Research undertaken by Cambridge University, UK)


ANCA Associated Vasculitis: Are genes important

Report by Professor Lorraine Harper, Birmingham University Hospital. Vasculitis UK Newsletter/Journal, Spring 2011, page 8. Available to view at:

ANCA Associated Vasculitis

Paper by Dr Richard Watts and Dr Chethana Dharmapalaiah for Arthritis Research UK, Issue 1 (Topical Reviews Series 7) Autumn 2012. Paper available at: ARUK Topical Reviews

Clinical trial of Rituximab as maintenance treatment of vasculitis

(proposed in late 2010). The trial is to be the responsibility of Dr David Jayne of Addenbrookes, Cambridge. The aim is to study Rituximab as a maintenance treatment for vasculitis. For further details please contact Dr Jayne by e-mail: e-mail Dr David Jayne

Immune system and autoimmunity

Dr Julie Williams, Birmingham University Hospital. Reported in Vasculitis UK Newsletter/ Journal. Autumn 2011 Available to view at:

“Increased risk of autoimmune diseases in families with Wegener’s Granulomatosis”

(Abstract) The Journal of Rheumatology – Oct 2010


Monoclonal antibody no better than standard treatment but Rituximab may be better for relapsing vasculitis

Review written by Maya Anaokar on review of two articles published in the New England Journal of Medicine, 2010. Reviewed in Vasculitis UK Newsletter/Journal. Autumn 2010, page 10. Available to view at:

Modern management of primary systemic vasculitis

Ed: Richard Watts – Clinical Medicine. Vol 7, No. 1 Jan/Feb 2007

Ongoing laboratory research

Dr Neil Holden, Birmingham University Hospital

The immune system and basis of ANCA associated vasculitis and All ANCA are equal but some ANCA are more equal than others. Reported in Vasculitis UK Newsletter/Journal, Autumn 2010, page 8/9. Available to view at:

Randomized Trial of Rituximab Versus Cyclophosphamide for ANCA – Associated Renal Vasculitis

Rachel B Jones et al

  • N Engl J Med 2010; 363:211-220 July 15, 2010

Update from Birmingham on Cutting Edge Research into Vasculitis

Julie Williams

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H Stone et al – N Engl J Med 2010; 363:221-232 July 15, 2010. A review of this paper can be found in the Vasculitis UK Newsletter/Journal, Spring 2011 Available to view at:

Vasculitis DNA Bank for Glomerulonephritides

(as at Dec 2010). The Vasculitis DNA bank at Birmingham, housed in the Wellcome Trust Clinical Research Facility, is still actively collecting samples from patients, spouses and relatives. Taking part in the research will be helping the research team to establish whether genetics or possibly environmental factors are triggers in the disease process.

For further information write to: Wellcome Trust Clinical Research Facility, UHB NHS Foundation Trust, Birmingham, B15 2TH